Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WST03
- Development stage
- Phase 2
- Lead developer
- Shanghai Sine
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Topical
01
Overview
WST03 is an investigational live biotherapeutic product (LBP) developed by Shanghai Sine Pharmaceutical Laboratories, a subsidiary of Shanghai Pharma, for the treatment of bacterial vaginosis (BV). It consists of a specific strain of *Lactobacillus crispatus*, a commensal bacterium that is a hallmark of a healthy vaginal microbiome. WST03 is designed to be administered intravaginally to replenish the *Lactobacillus* population, which is typically depleted in patients suffering from BV. By colonizing the vaginal epithelium and producing lactic acid, hydrogen peroxide, and other antimicrobial substances, WST03 helps restore a low vaginal pH and inhibits the overgrowth of anaerobic pathogens such as *Gardnerella vaginalis*. As a Class 1 biological new drug in China, it represents a targeted approach to microbiome restoration rather than traditional antibiotic treatment.
- Other names
- Lactobacillus crispatus vaginal capsule
Beyond the preview
Go deeper on WST03.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WST03.